Novo-Glyburide en es it fr

Novo-Glyburide Brand names, Novo-Glyburide Analogs

Novo-Glyburide Brand Names Mixture

  • No information avaliable

Novo-Glyburide Chemical_Formula


Novo-Glyburide RX_link

Novo-Glyburide fda sheet

Novo-Glyburide msds (material safety sheet)

Novo-Glyburide MSDS

Novo-Glyburide Synthesis Reference

Weber et al., U.S. Pat. 3,454,635 (1969)

Novo-Glyburide Molecular Weight

494.004 g/mol

Novo-Glyburide Melting Point


Novo-Glyburide H2O Solubility

4 mg/L

Novo-Glyburide State


Novo-Glyburide LogP


Novo-Glyburide Dosage Forms

Tablet (1.25 mg, 2.5 mg, 5 mg)

Novo-Glyburide Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Novo-Glyburide Pharmacology

Glyburide, a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.

Novo-Glyburide Absorption

Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.

Novo-Glyburide side effects and Toxicity

Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.

Novo-Glyburide Patient Information

Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure also should be explained.

Novo-Glyburide Organisms Affected

Humans and other mammals